Pricing Log in Create free account
Saturday 17 October 2026 Export GILD’s income statement to Excel — free account

Gilead Sciences, Inc.

GILD Healthcare Drug Manufacturers General

Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS fell 638.2%, free cash flow grew 376.8% and total debt rose 5.21%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; dividend growth for ten consecutive years.

156.19 1.18 −0.75%
Market cap
$195.1B
P/E
0.0×
Fwd P/E
−46.2×
Dividend yield
2.08%
F-score
8/9
Altman Z
4.03
Beneish M
−2.45
Dividend safety
77/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Gilead Sciences, Inc. (GILD) Operating cash flow

Alert me on Operating cash flow

Gilead Sciences, Inc.'s operating cash flow for fiscal 2025 was $10.0B, down 7.47% from $10.8B in fiscal 2024. Over the twelve months to 30 June 2026 it was $13.6B. Over the past ten years it has ranged from $8.0B (fiscal 2023) to $21.3B (fiscal 2015); the current reading is higher than 55% of that period. Gilead Sciences, Inc. ranks 9th of 21 Drug Manufacturers General companies by operating cash flow.

Operating cash flow, annual

Embed this chart

Annual newest first

Period Operating cash flow Change
FY2025 $10.0B (7.47%)
FY2024 $10.8B 35.25%
FY2023 $8.0B (11.75%)
FY2022 $9.1B (20.31%)
FY2021 $11.4B 39.37%
FY2020 $8.2B (10.67%)
FY2019 $9.1B 8.86%
FY2018 $8.4B (29.40%)
FY2017 $11.9B (30.20%)
FY2016 $17.0B (19.78%)

Quarterly newest first

Period Operating cash flow Change
Jun 2026 $3.6B 40.45%
Mar 2026 $2.5B (23.53%)
Dec 2025 $3.3B (19.01%)
Sep 2025 $4.1B 396.74%
42 more quarters

Against its own ten years

Low $8.0B High $21.3B
Ten-year median $10.0B
Current reading's percentile 55

Operating cash flow against peers

Company Operating cash flow
NVO Novo Nordisk A/S compare $20.4B
MRK Merck & Co., Inc. compare $20.0B
NVS Novartis AG compare $18.4B
AZN AstraZeneca PLC compare $13.7B
GILD Gilead Sciences, Inc. $13.6B
PFE Pfizer Inc. compare $13.4B
BMY Bristol Myers Squibb Company compare $12.8B
AMGN Amgen Inc. compare $12.5B
GSK GSK PLC Sponsored ADR compare $11.0B

What Operating cash flow is

Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.

Reported line item

The full definition of Operating cash flow →

More on GILD